Heterogeneity of myocardial iron distribution in response to chelation therapy in patients with transfusion-dependent anemias

被引:0
|
作者
Kate Hanneman
Vikram M. Raju
Hadas Moshonov
Richard Ward
Bernd J. Wintersperger
Andrew M. Crean
Heather Ross
Elsie T. Nguyen
机构
[1] University of Toronto,Division of Cardiothoracic Imaging, Department of Medical Imaging, University Health Network, Toronto General Hospital
[2] University of Toronto,Division of Hematology, Department of Medicine, Toronto General Hospital
[3] University of Toronto,Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network
关键词
Magnetic resonance imaging; T2* imaging; Thalassemia; Iron overload; Cardiomyopathy;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this study is to examine the effect of different iron chelation regimens on the distribution of myocardial iron in patients with transfusion-dependent anemias. Institutional review board approval was obtained. Patients treated with iron chelation therapy who had undergone baseline and 1-year follow-up cardiac T2* MR studies in a four-year period were identified retrospectively. One hundred and eight patients (44 % male, mean age 31.6 ± 9.7 years) were included. The interventricular septum on three short-axis slices (basal, mid and apical) was divided into anterior and inferior regions of interest for T2* analysis. Cardiac iron concentration (CIC) was calculated from T2* values. Statistical analysis included analysis of variance and paired t-test, using Bonferroni adjustment in all pairwise comparisons. At baseline, T2* measurements varied significantly across all six regions (p < 0.001): lowest in the mid anteroseptum (mean 22.3 ± 10.1 ms) and highest in the apical inferoseptum (mean 26.2 ± 12.8 ms). At follow-up, T2* and CIC values improved significantly in all segments [mean change of 3.78 ms (95 % CI (2.93, 4.62), p < 0.001) and 0.23 mg/g (95 % CI (0.16, 0.29), p < 0.001), respectively]. Change in T2* values varied significantly between segments (p < 0.001) with greatest improvement in the apical inferoseptum [4.26 ms, 95 % CI (2.42, 6.11)] and least improvement in the basal anteroseptum [2.95 ms, 95 % CI (1.37, 4.54)]. The largest improvement in T2* values was noted in patients treated with deferiprone [4.96 ms, 95 % CI (2.34, 7.58)]. There was a statistically significant difference in improvement in CIC values between chelation regimens (p = 0.016). This is the first study to report heterogeneity in response to iron chelating drugs with variable segmental changes in T2* values.
引用
收藏
页码:1517 / 1526
页数:9
相关论文
共 50 条
  • [1] Heterogeneity of myocardial iron distribution in response to chelation therapy in patients with transfusion-dependent anemias
    Hanneman, Kate
    Raju, Vikram M.
    Moshonov, Hadas
    Ward, Richard
    Wintersperger, Bernd J.
    Crean, Andrew M.
    Ross, Heather
    Nguyen, Elsie T.
    INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2013, 29 (07): : 1517 - 1526
  • [2] Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion-Dependent Anemias
    Viprakasit, Vip
    Gattermann, Norbert
    Lee, Jong Wook
    Porter, John B.
    Taher, Ali
    Habr, Dany
    Roubert, Bernard
    Domokos, Gabor
    Cappellini, Maria Domenica
    BLOOD, 2010, 116 (21) : 1733 - 1734
  • [3] Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias
    Kwiatkowski, JL
    Cohen, AR
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (06) : 1355 - +
  • [4] Iron chelation therapy in patients with transfusion-dependent myelodysplastic syndrome
    Mast, Alan E.
    Field, Joshua J.
    TRANSFUSION, 2012, 52 (10) : 2078 - 2080
  • [5] Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients
    Oliva, Esther Natalie
    Ronco, Francesca
    Marino, Antonio
    Alati, Caterina
    Pratico, Giulia
    Nobile, Francesco
    TRANSFUSION, 2010, 50 (07) : 1568 - 1570
  • [6] IRON OVERLOAD AND IRON CHELATION THERAPY WITH DEFERASIROX IN TRANSFUSION-DEPENDENT PATIENTS WITH MYELODYSPLASTIC SYNDROMES
    Del Corso, L.
    Bacigalupo, A.
    Balleari, E.
    Bellodi, A.
    Calzamiglia, T.
    Da Col, A.
    D'elia, P.
    Dominietto, A.
    Favorini, S.
    Forni, G.
    Galimberti, S.
    Ghio, M.
    Ghio, R.
    Salvetti, C.
    Ubezio, G.
    Vignolo, L.
    Molinari, E.
    Ghiso, A.
    Drousseau, M.
    Simonetti, F.
    Goretti, R.
    Tassara, R.
    Racchi, O.
    Scudeletti, M.
    Arboscello, E.
    Gianluca, F.
    LEUKEMIA RESEARCH, 2015, 39 : S150 - S150
  • [7] Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia
    Jamuar, Saumya S.
    Lai, Angeline H. M.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (05) : 299 - 307
  • [8] Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia
    Jamuar, Saumya Shekhar
    Lai, Angeline Hwei Meeng
    Tan, Ah Moy
    Chan, Mei Yoke
    Tan, Ee Shien
    Ng, Ivy Swee Lian
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2011, 47 (11) : 812 - 817
  • [9] A Study to Assess and Improve Adherence to Iron Chelation Therapy in Transfusion-Dependent Thalassemia Patients
    Theppornpitak, Krisada
    Trakarnsanga, Bussaba
    Lauhasurayotin, Supanun
    Poparn, Hansamon
    Chiengthong, Kanhatai
    Sosothikul, Darintr
    Techavichit, Piti
    HEMOGLOBIN, 2021, 45 (03) : 171 - 174
  • [10] Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
    Cappellini, Maria Domenica
    Porter, John
    El-Beshlawy, Amal
    Li, Chi-Kong
    Seymour, John F.
    Elalfy, Mohsen
    Gattermann, Norbert
    Giraudier, Stephane
    Lee, Jong-Wook
    Chan, Lee Lee
    Lin, Kai-Hsin
    Rose, Christian
    Taher, Ali
    Thein, Swee Lay
    Viprakasit, Vip
    Habr, Dany
    Domokos, Gabor
    Roubert, Bernard
    Kattamis, Antonis
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (04): : 557 - 566